BM
Biomerica, Inc.
BMRA · NASDAQ
$2.39 +3.91% (+$0.09)
1M +14.35%
Market Cap $7.39M
P/E Ratio -
Div. Yield -
ROE 97.19%
Bulios Fair Price
$1.49
37.7% downside
Current Price
$2.39
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMRA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
78 /100
Cheap P/B 2.81x
P/S 1.66x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 39.24%
Rev. growth 5.87%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 119.54%
Gross margin 8.09%
FCF margin 77.67%
Quality
8 /100
Poor ROA 55.85%
ROIC 118.62%
Asset turnover 0.66x
Debt
72 /100
Low Current ratio 1.62x
Debt/Equity 0.72x
Debt/Assets N/A
Stability
36 /100
Moderate EPS volatility 308.31%
Beta 0.31x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMRA
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Zackary S. Irani
Employees
50
Headquarters
Irvine
Upcoming events
21 OCT
Earnings
Upcoming earnings report